

Research Article

Antimicrobial Resistance Profile and Associated Factors of Group B Streptococci Colonization among Pregnant Women Attending Antenatal Clinics in Jigjiga, Southeast Ethiopia

Addisu Tesfaye,¹ Addisu Melese ,² and Awoke Derbie ^{2,3,4}

¹Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Jigjiga University, Jigjiga, Ethiopia

²Department of Medical Microbiology, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia

³Center for Innovative Drug Development and Therapeutic Trial for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia

⁴Biotechnology Research Institute, Bahir Dar University, Bahir Dar, Ethiopia

Correspondence should be addressed to Awoke Derbie; awoke.derbie@bdu.edu.et

Received 7 October 2021; Accepted 13 March 2022; Published 31 March 2022

Academic Editor: Joseph Falkinham

Copyright © 2022 Addisu Tesfaye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. *Streptococcus agalactiae* (group B *Streptococcus*, GBS) is one of the causes of maternal and neonatal morbidity and mortality in many parts of the world. It is associated with severe maternal and neonatal outcomes. The colonization rate, associated factors, and antimicrobial sensitivity (AST) profile of GBS among pregnant women in Eastern Ethiopia is less studied. **Methods.** A cross-sectional study was conducted from 1st March to 30th May, 2021 in Jigjiga. A total of 182 pregnant women with a gestational period of ≥ 36 weeks were included. A structured questionnaire was used to collect data on the participants' demographic and clinical history. Vaginal-rectal samples were collected by brushing the lower vagina and rectum with a sterile cotton swab for bacteriological culture. An antimicrobial sensitivity test (AST) was performed using the Kary-Bauer disk diffusion method. Data were entered and analyzed using SPSS version 25. The logistic regression model was used to find out factors associated with GBS colonization. **Results.** GBS colonization among pregnant women attending antenatal care was at 15.9% (29/182). The AST result showed that the majority of the isolates were sensitive to vancomycin (96.6%), chloramphenicol (96.6%), ampicillin (93.1%) azithromycin (89.7%), and penicillin (86.2%). In contrast, the isolates were found to be resistant to ceftriaxone, erythromycin, ciprofloxacin, clindamycin, and tetracycline at 17.2%, 20.7%, 27.6%, 27.6%, and 34.5%, respectively. Multidrug resistance (MDR) was noted in 4 isolates (13.79%). GBS colonization was significantly associated with history of preterm labor (<37 weeks of gestation) (AOR = 3.87, 95% CI = 1.36–10.9) and a history of prolonged ruptured membrane (>18 hr.) (AOR = 3.44, 95% CI = 1.34–8.83). **Conclusions.** The colonization rate of GBS was considerably high among pregnant women attending antenatal care in the present study area. The observed antimicrobial resistance for the common drugs and the reported MDR level calls for routine screening of pregnant women for GBS and actions to minimize antimicrobial resistance (AMR) should be strengthened.

1. Introduction

Streptococcus agalactiae, also called group B *Streptococcus* (GBS), is part of the normal flora of gastrointestinal and genital tracts [1]. The bacteria use numerous adhesins and stress response apparatuses and immune evasion schemes for vaginal colonization [2]. The lower intestinal tract is the most likely reservoir of the bacteria with a secondary spread to the genitourinary system. The risk of colonization of GBS

is greater among infants who are born from mother with GBS colonization. GBS transmission is vertical, transmitted throughout labor, or in utero through the transmission of the bacteria from the vaginal or the mucosa that is anorectally colonized [3].

During the time of pregnancy, the colonization of GBS could be brief, chronic, or intermittent [4]. Colonization commonly does not show any symptoms. However, at some point in pregnancy, GBS multiplication around the vaginal

area can lead to maternal morbidity as likely as neonatal complications [5]. About 10 to 30% of women of child-bearing age lift GBS in the recto-vaginal area without showing any symptoms. When untreated, nearly 50–75% of neonates born from a GBS infected mothers could be potentially colonized [6]. In Ethiopia, studies revealed that maternal colonization of GBS ranges from 7.2% [7] to 20.9% [3].

Different factors are associated with GBS colonization. The history of premature rupture of membranes, gastrointestinal GBS colonization, increased maternal age, low vitamin D intake, poor personal hygiene, sexual intercourse, health care occupation, and illiteracy were reported as important associated factors with GBS vaginal colonization [8–10].

GBS is one of the leading cause of infections among neonates worldwide [11–13]. In 2017, the World Health Organization (WHO) stated that infection associated with GBS caused about 147,000 infant deaths worldwide, despite the use of intrapartum antibiotic prophylaxis (IAP). With 54% of estimated cases and 65% of stillbirths and infant deaths, Africa had the highest burden [14]. While majority of GBS infections could be detected during labor or delivery, women in their post-delivery period can also be at a greater risk for invasive GBS complications even in the absence of extra risk factors [15]. The early onset of GBS infection may cause severe neurological damages and other serious neonatal outcomes [16–20].

With regard to the antimicrobial sensitivity profile of GBS, it is regarded as uniformly susceptible to penicillin, the first-line antibiotic for Intrapartum Antibiotics Prophylaxis (IAP) [11]. Macrolides (e.g., erythromycin) and lincosamides (e.g., clindamycin) are used as alternative drugs [12]. However, the global spread of antimicrobial resistance (AMR) has led to increased GBS infections among pregnant women and newborns that are difficult to treat and poses significant health concerns. Increased use of antimicrobials for prophylaxis without proper bacteriological screening is one factor that raises this concern [21]. GBS is becoming resistant to different antibiotics, including macrolides and lincosamides, and recently resistance to penicillin and fluoroquinolone was also reported [22]. A systematic review and meta-analysis conducted in China showed that significant rates of resistance to erythromycin, clindamycin, and tetracycline were observed; 0–86%, 4–84%, and 23–96%, respectively [23]. Another meta-analysis that summarized findings from 21 Africa countries also revealed that antibiotic resistance for GBS is a major concern for the whole continent. Higher antimicrobial resistance was observed against tetracycline at 82.6% and penicillin at 33.6% [24].

A previous epidemiological study conducted in two hospitals in Jigjiga, Ethiopia, discovered neonatal sepsis (24.4%) and neonatal deaths (5.7%) as a major serious issue. The study also indicates that 96% of deaths were early neonatal deaths that occurred in the first one week of life [25]. However, there is quite limited data on the colonization rate, antimicrobial susceptibility profile, and associated factors of GBS in Eastern Ethiopia and in the present study area in particular. Therefore, our study was aimed at the

description of colonization, antimicrobial susceptibility profile, and associated factors of GBS among pregnant women.

2. Materials and Methods

2.1. Study Design, Area, and Period. An institution-based cross-sectional study was conducted at two selected health facilities of Jigjiga from 01 March 2021 to 30 May 2021. Jigjiga is located in the Southeastern part of Ethiopia, 621 km from the capital, Addis Ababa. The city is situated 1934 meters above the mean sea level. Based on the Ethiopian Central Statistical Agency report of the year 2015, the city had an estimated population of 304,000 of which 151,422 were men. There were two hospitals and four health centers providing delivery services in the city during the time of data collection. For this study, Jigjiga University Sultan Sheik Hassen Yabere Referral Hospital (JJUSSHYRH) and Kar-amara General Hospital (KGH) were selected because these hospitals had the largest client flow for antenatal care and delivery services.

2.2. Study Population and Sampling. Our study population were pregnant women with a gestational age of ≥ 36 weeks attending antenatal clinics at JJUSSHYRH and KGH during the time of data collection. The sample size was calculated based on the proportion of GBS colonization among pregnant women reported in Harar, Ethiopia, at 13.68% [26]. Using single population proportion formula, our calculated sample size was at 182. The sample size was proportionally allocated to each health facility based on their three months pregnancy visits. Accordingly, 123 and 52 participants were recruited from JJUSSHYRH and KGH, respectively.

2.3. Data Collection. A pretested and structured questionnaire was used to collect data on the demographic, and clinical characteristics of the study participants. Demographic data such as maternal age, residence, marital status, occupation, educational status and clinical data such as gravidity, prenatal care, urinary tract infection, outcomes of the previous delivery, prolonged rupture of membrane, and gestational age were collected.

2.4. Specimen Collection, Transportation, and Bacteriological Analysis. Vaginal-rectal swabs were collected during the antenatal care (ANC) follow-up by brushing the lower vagina and rectum with a sterile cotton swab by trained nurses following universal precautions. The swabs were immediately transported to the microbiology laboratory, JJUSSHYRH, within 2–4 hours using Amies transporting media maintaining the temperature at 37.

The bacteriological analysis was performed following the methods described in the center for disease control and prevention (CDC), and the American Society for Microbiology [27, 28]. Samples were inoculated on Todd Hewitt broth media supplemented with gentamycin and nalidixic

TABLE 1: Demographic characteristics of the participants at JJUSSHYRH and KGH in Jigjiga city, Southeast Ethiopia, March–May, 2021.

Variable	Sociodemographic-characteristics		
	Categories	Frequency	Percentage (%)
Health facility	JJUSSHYRH	123	67.60
	KGH	59	32.40
Age group in years	15–19	15	8.20
	20–24	39	21.40
	25–29	65	35.70
	30–34	33	18.10
	≥35	30	16.50
Marital status	Single	26	14.30
	Married	116	63.70
	Divorced	29	15.90
	Widowed	11	6.00
Residence	Urban	126	69.20
	Rural	56	30.80
Occupation	Civil servant	15	8.20
	Student	19	10.40
	Housewife	68	37.40
	Self-employee	22	12.10
	Daily labour	24	13.20
	Farmer	10	5.50
	Merchant	24	13.20
Educational status	Had no formal education	83	45.60
	Primary school	40	22.00
	Secondary school	38	20.90
	College/University	21	11.50
Religion	Muslim	137	75.30
	Christian	123	24.70

acid and incubated at 37°C for 24 hours, then subcultured on a blood agar plate at 37°C for 24 hrs. Colony characteristics, Gram-stain, and catalase test were used for presumptive identification. All Gram-positive cocci, beta-hemolytic, and catalase-negative isolates were further identified by Christie–Atkins–Munch–Petersen (CAMP) and bacitracin tests. The CAMP test was used to identify CAMP-positive GBS from other beta-hemolytic Streptococci. In brief, *Staphylococcus aureus* was inoculated onto a sheep blood agar plate by making a narrow streak down the center of the plate with a loop. Then, the test organism (GBS) was streaked in a straight-line inoculum at right angles to the *S. aureus* within 2 mm. The plates were incubated at 35°C for 24 h. A positive CAMP test was indicated by an “arrowhead” shaped enhanced zone of beta-hemolysis in the area between the two cultures with the “arrow point” toward the *S. aureus* streak. No enhanced zone of beta-hemolysis was observed in a CAMP negative reaction. In addition, the bacitracin test was used to differentiate GBS from group A streptococcus which are both beta-hemolytic [29].

2.5. Antimicrobial Sensitivity Testing (AST). AST was performed using the Kirby-Bauer disk diffusion method. Bacterial suspension was prepared by adding 4–5 GBS colonies of the same morphology in 5 ml of sterile physiological saline equal to a 0.5 McFarland’s standard that used as a reference to adjust the turbidity of the suspension. The

suspension was inoculated on Mueller–Hinton agar (MHA) plates supplemented with 5% defibrinated sheep blood. Then, antibiotic disks were placed and incubated at 35–37°C overnight. GBS were tested against antibiotics that are recommended by CLSI guideline. The zone of inhibition around antibiotic disks was measured by a calibrated ruler and interpreted as sensitive, intermediate, or resistant [30].

2.6. Data Quality Control. Standard operating procedures (SOPs) were followed during the sample collection, transportation, and bacteriological processing steps. Standard strains: *Streptococcus agalactiae* (American Type Culture (ATCC) 27956), *Staphylococcus aureus* (ATCC 24923), *Streptococcus pyogenes* (ATCC 19615), and *Escherichia coli* (ATCC 25922) were used as quality control for culture and antimicrobial sensitivity testing.

2.7. Data Analysis. Data were coded, cleaned, and entered into SPSS V.25 for analysis. Generated data were compiled by frequency tables and figures and other statistical summary measures. Bi-variable logistic regression analysis was carried out to identify the possible associated factors with GBS colonization. Variables with p -value ≤ 0.25 were further entered in to the multivariable logistic regression analysis. Finally, the results were presented using AOR with its 95% CI at p -value < 0.05 .

TABLE 2: Clinical characteristics of the participants at JJUSSHYRH and KGH in Jigjiga city, Southeast Ethiopia, March–May, 2021.

Variables	Clinical-characteristics		
	Categories	Frequency	Percentage (%)
Gravidity	Primigravida	44	24.20
	Multigravida	138	75.80
History of abortion	Yes	46	25.30
	No	136	74.70
History of stillbirth	Yes	22	12.10
	No	160	87.90
Antenatal care visit	Yes	130	71.40
	No	52	28.60
History of antimicrobial therapy	Yes	6	3.30
	No	176	96.70
History of contraceptive use	Yes	49	26.90
	No	133	73.10
HIV status	Positive	14	7.70
	Negative	168	92.30
Prolonged rupture of membrane >18 hr	Yes	35	19.20
	No	147	80.80
History of urinary tract infection	Yes	49	26.90
	No	133	73.10
Diabetes	Yes	12	6.60
	No	170	93.40
Pregnancy-induced hypertension	Yes	6	3.30
	No	176	97.70
History of neonatal death	Yes	28	15.40
	No	154	84.60
History of preterm labour (<37 weeks)	Yes	24	13.20
	No	158	86.80

TABLE 3: Antimicrobial sensitivity profile of GBS isolated from pregnant women at JJUSSHYRH and KGH in Jigjiga city, Southeast Ethiopia, March–May, 2021.

Antimicrobial	Disk potency (μg)	Sensitive <i>N</i> (%)	Intermediate <i>N</i> (%)	Resistant <i>N</i> (%)
Penicillin G	10	25 (86.2)	—	4 (13.8)
Ampicillin	10	27 (93.1)	—	2 (6.9)
Clindamycin	2	18 (62.1)	3 (10.3)	8 (27.6)
Erythromycin	15	23 (79.3)	0	6 (20.7)
Chloramphenicol	30	28 (96.6)	0	1 (3.4)
Ciprofloxacin	5	21 (72.4)	0	8 (27.6)
Ceftriaxone	30	24 (82.8)	—	5 (17.2)
Vancomycin	30	28 (96.6)	—	1 (3.4)
Azithromycin	15	26 (89.7)	0	3 (10.3)
Tetracycline	30	15 (51.7)	4 (13.8)	10 (34.5)

3. Results and Discussion

3.1. Characteristics of the Study Participants. A total of 182 pregnant women were included in the study. One hundred twenty-three (67.6%) of the participants were from Jigjiga University Sultan Sheik Hassan Yabere Referral Hospital and the remaining were from Karamara General Hospital. The mean age of the participants was 27.77 ± 5.79 . Most of them at 65 (35.7%), 116 (63.7%), 126 (69.2%), 83 (45.6%), and 137 (75.3%) were in the age group of 25–29 years, married, were living in an urban setting, had no formal education, and were Muslims in terms of religion (Table 1).

With regard to the reproductive history of the participants, 138 (75.8%) were multigravida, 46 (25.3%) had a history of abortion, 22 (12.1%) had a history of stillbirth, and 28 (15.4%) had a history of neonatal death. The majority of the study participants at 130 (71.4%) had antenatal visits and about 133 (73.1%) had no history of contraceptive use. Twenty-four (13.2%) of the participants had a history of preterm labor and 35 (19.2%) had prolonged membrane rupture (Table 2).

3.2. Group B Streptococci (GBS) Colonization. The vaginal-rectal colonization of GBS among pregnant women was at 29

TABLE 4: Multidrug resistance (MDR) profile of GBS isolates from pregnant women at JJUSSHYRH and KGH in Jigjiga city, Southeast Ethiopia, March–May, 2021.

Antibiotic combination	Frequency (%)	Remark
ERY: CD	3 (10.34)	—
P: TE	1 (3.44)	—
CTX: TE	1 (3.44)	—
CD:TE	2 (6.9)	—
CD: CTX	1 (3.44)	—
P: CTX	1 (3.44)	—
ERY: CD: CIP	2 (6.9)	MDR
AMP: TE: CIP	1 (3.44)	MDR
ERY: CD: CIP:TE	1 (3.44)	MDR

* ERY: Erythromycin CD: Clindamycin P: Penicillin TE: Tetracycline CTX: Ceftriaxone CIP: Ciprofloxacin AMP: Ampicillin.

(15.93%). Of these, 17 (58.6%) were from JUSSHYRH and the remaining 12 (41.4%) were from KGH. There is no statistical difference (p -value = 0.26) on the proportion. Our finding is comparable with other studies conducted in other parts of the world; Iran (13.65%) [31], Tanzania (16.5%) [32], Cameron (14%) [33], East Africa (15.4%) [24], and Ethiopia, (13.7%) [34, 35]. However, our finding was found to be higher than studies conducted in Turkey, Iran and Italy (<10%) [36], Kenya (12%) [37], Nigeria (9.8%) [38], and Ethiopia (7.2–13.2%) [7, 39, 40]. The finding of this study was also found lower than other similar studies conducted in Saudi Arabia (27.4%) [41], Malawi (23%) [42], Kenya (25.2%) [43], Nigeria (18%) [44], Egypt (26.8%) [45], and Ethiopia (19–25%) [3, 36, 46]. The difference in the proportion of GBS colonization among different studies in Ethiopia and elsewhere in the world might be explained by the difference in geographical setting, difference in sample size, difference in personal hygiene practice, and the type of culture media used to isolate GBS.

3.3. Antimicrobial Susceptibility Profile of GBS Isolates. In this study, most of the GBS isolates were found to be sensitive to vancomycin and ampicillin. In contrary, they showed a moderate level of resistance for tetracycline 10 (34.5%), clindamycin 8 (27.6%), and ciprofloxacin 8 (27.6%) (Table 3). Penicillin is the first choice for IAP and ampicillin as an alternative [5]. Studies conducted around the world, including reports in Ethiopia showed that these drugs have better action against GBS than other antibiotics [3, 34, 47, 48]. In our study, the resistance of both penicillin and ampicillin was at 13.8% and 6.9%, respectively, which implies that these drugs are still good as a first choice to manage pregnant women colonized with GBS. Clindamycin and erythromycin could also be considered for patients who are allergic to penicillin once AST is performed [5]. Our finding is comparable with the studies conducted in Switzerland (8.2%) [49], Iran, Tehran (14.6%) [26], Egypt (22.6%) [50], Kenya (30.4%) [51], and Ethiopia (17.6–26.8%) [48, 52].

We reported better sensitivity of GBS for chloramphenicol and azithromycin at 96.6% and 89.2%, respectively. This result is concurring with other findings reported in Egypt [50] and similar studies in Ethiopia [52, 53].

Vancomycin was also one of the commonly utilized drugs for patients who poorly responded for clindamycin and for the cases with a risk of high anaphylaxis. In this study, GBS isolates were found with 96.6% sensitivity for vancomycin which was similar with other studies conducted in Iran [26], Brazil [54], Cameron [33], Egypt [50], and Ethiopia [34, 48] where GBS isolates were found 100% sensitive.

Multidrug resistance was observed in 4 isolates (13.79%) as presented in Table 4. This finding is similar with other studies in Ethiopia that reported 15.8%–43.9% MDR GBS isolates [34, 52]. In general, the high level of AMR reported in our study might be associated with different factors including but not limited to the over and misuse of drugs in the study area where there is a weak drug regulatory practice and scarce bacteriological surveillance system because of lack of routine AST testing. Most of the antimicrobials listed above are available in the local market and individuals usually use these drugs without physician prescription.

3.4. Factors Associated with Colonization of GBS. In the multivariable analysis, most of the variables tested in the regression model did not show statistical association with GBS colonization among pregnant women. Only two factors were found to be statistically significant; history of preterm labor (<37 weeks of gestation) (AOR = 3.87, 95% CI = 1.36–10.9, p -value = 0.01) and history of premature rupture of membrane (PROM) (>18 hr.) (AOR = 3.44, 95% CI = 1.34–8.83, p -value = 0.01). This finding is in line with other similar studies conducted in China [55], Nigeria [56], and Ethiopia [35, 48, 57]. According to different reports, GBS infection during pregnancy can cause complications like miscarriage, premature labor, or stillbirth. Likewise, PROM is also most often due to an infection in the uterus, cervix, or vagina, in this case; GBS might be an important component that should be ruled out.

As a limitation, neonatal outcomes are not included in our report since neonates born from the study participants were not included due to constraints.

4. Conclusions

The colonization rate of GBS was considerably high among pregnant women attending antenatal care in the present study area. In this study, most GBS isolates were found sensitive to vancomycin, chloramphenicol, ampicillin, azithromycin, and penicillin. However, the resistance to tetracycline, clindamycin, ciprofloxacin, erythromycin, and ceftriaxone was significant. GBS colonization was found significantly associated with history of preterm labor and premature rupture of membrane. Therefore, stakeholders should consider routine culture-based bacteriological screening of pregnant women to help guide proper IAP. Actions to minimize AMR should be strengthened. Further large-scale studies that include neonatal outcome of GBS positive mothers should be considered.

4.1. Declarations. Ethical approval: Ethical clearance was obtained from Bahir Dar University College of Medicine and Health Science institutional review board (IRB). Moreover, written informed consent was obtained from all the study participants and for those participants under the age of 16 years, written informed consent was secured from their parents or guardian. Client identifiers, including names and IDs, were also kept confidential, and any other special data security requirements were maintained and assured. Bacteriological results were communicated for health professionals attending the pregnant women.

Data Availability

All the generated data are included in this manuscript. The original data source can be shared up on request of the principal investigator.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

AT conceived the research idea. AT was also involved in the data collection and interpretation of the result. AD was involved in data analysis and evaluating the scientific content of the study. AM was involved in rationalizing the method section and manuscript preparation. All authors read and approved the final manuscript for submission.

Acknowledgments

The authors would like to acknowledge all the participants. The authors would also like to thank the two hospital staff members who helped us in the data collection process. Finally, the authors would like to extend their deepest gratitude to Bahir Dar and Jigjiga Universities. This project was partially funded by Bahir Dar University, College of Medicine and Health Sciences, Ethiopia.

References

- [1] P. Wang, J. Tong, X. Ma et al., "Serotypes, antibiotic susceptibilities, and multi-locus sequence type profiles of *Streptococcus agalactiae* isolates circulating in Beijing, China," *PLoS One*, vol. 10, no. 3, Article ID e0120035, 2015.
- [2] K. A. Patras and V. Nizet, "Group b streptococcal maternal colonization and neonatal disease: molecular mechanisms and preventative approaches," *Frontiers in Pediatrics*, vol. 6, p. 27, 2018.
- [3] M. Mohammed, D. Asrat, Y. Woldeamanuel, and A. Demissie, "Prevalence of group b *Streptococcus* colonization among pregnant women attending antenatal clinic of hawassa health center, hawassa, Ethiopia," *The Ethiopian Journal of Health Development*, vol. 26, no. 1, pp. 36–42, 2012.
- [4] J. Chen, J. Fu, W. Du et al., "Group b streptococcal colonization in mothers and infants in western China: prevalences and risk factors," *BMC Infectious Diseases*, vol. 18, no. 1, pp. 291–298, 2018.
- [5] L. McGee, S. Schrag, and J. R. Verani, *Prevention of Perinatal Group B Streptococcal Disease*, Cdc, Atlanta, GA, USA, 2010.
- [6] N. Premanatham, M. S. John, and P. S. Reddy, "Prevalence of vaginal colonisation of group b streptococci in pregnant women attending tertiary care hospital and its transmission to neonates," *International Journal of Current Microbiology and Applied Sciences*, vol. 4, no. 2, pp. 225–230, 2015.
- [7] Z. L. Woldu, T. G. Teklehaimanot, S. T. Waji, and M. Y. Gebremariam, "The prevalence of group b streptococcus recto-vaginal colonization and antimicrobial susceptibility pattern in pregnant mothers at two hospitals of addis ababa, Ethiopia," *Reproductive Health*, vol. 11, no. 1, p. 80, 2014.
- [8] F. Alp, D. Findik, H. T. Dagi, U. Arslan, A. T. Pekin, and S. A. Yilmaz, "Screening and genotyping of group b *Streptococcus* in pregnant and non-pregnant women in Turkey," *The Journal of Infection in Developing Countries*, vol. 10, no. 3, pp. 222–226, 2016.
- [9] C. C. Akoh, E. K. Pressman, E. Cooper, R. A. Queenan, J. Pillittere, and K. O. O'Brien, "Prevalence and risk factors for infections in a pregnant adolescent population," *Journal of Pediatric and Adolescent Gynecology*, vol. 30, no. 1, pp. 71–75, 2017.
- [10] H. N. Winn, "Group b *Streptococcus* infection in pregnancy," *Clinics in Perinatology*, vol. 34, no. 3, pp. 387–392, 2007.
- [11] S. Teatero, P. Ferrieri, I. Martin, W. Demczuk, A. McGeer, and N. Fittipaldi, "Serotype distribution, population structure, and antimicrobial resistance of group b *Streptococcus* strains recovered from colonized pregnant women," *Journal of Clinical Microbiology*, vol. 55, no. 2, pp. 412–422, 2017.
- [12] G. Gherardi, M. Imperi, L. Baldassarri et al., "Molecular epidemiology and distribution of serotypes, surface proteins, and antibiotic resistance among group b streptococci in Italy," *Journal of Clinical Microbiology*, vol. 45, no. 9, pp. 2909–2916, 2007.
- [13] G. Piccinelli, P. Fernandes, C. Bonfanti, F. Caccuri, A. Caruso, and M. A. De Francesco, "In vitro activity of solithromycin against erythromycin-resistant *Streptococcus agalactiae*," *Antimicrobial Agents and Chemotherapy*, vol. 58, no. 3, pp. 1693–1698, 2014.
- [14] WHO, "Group b *Streptococcus* infection, immunization, vaccines and biologicals," 2017, https://www.who.int/immunization/newsroom/press/news_group_b_strep_stillbirths_infant_deaths_2017/en.
- [15] D. Ke, C. Ménard, and F. J. Picard, "Rapid detection of group b streptococci," *Rapid Cycle Real-Time PCR—Methods and Applications: Microbiology and Food Analysis*, vol. 107, 2012.
- [16] J. K. Palmeiro, L. M. Dalla-Costa, S. E. L. Fracalanza et al., "Phenotypic and genotypic characterization of group b streptococcal isolates in southern Brazil," *Journal of Clinical Microbiology*, vol. 48, no. 12, pp. 4397–4403, 2010.
- [17] G. Konrad and A. Katz, "Epidemiology of early-onset neonatal group B streptococcal infection: implications for screening," *Canadian family physician Medecin de famille canadien*, vol. 53, no. 6, pp. 1055–1054, 2007.
- [18] M. Kohli-Lynch, N. J. Russell, A. C. Seale et al., "Neurodevelopmental impairment in children after group b streptococcal disease worldwide: systematic review and meta-analyses," *Clinical Infectious Diseases*, vol. 65, no. 2, pp. S190–S199, 2017.
- [19] B. Rojo-Bezares, J. M. Azcona-gutiérrez, C. Martin, M. S. Jareño, C. Torres, and Y. Sáenz, "Streptococcus agalactiae from pregnant women: antibiotic and heavy-metal

- resistance mechanisms and molecular typing," *Epidemiology and Infection*, vol. 144, no. 15, pp. 3205–3214, 2016.
- [20] M. Edwards, V. Nizet, and C. Baker, *Remington and Klein's Infectious Diseases of the Fetus and Newborn*, p. 411, Elsevier, Amsterdam, Netherlands, 2014.
- [21] C. Moraleda, R. Benmessaoud, J. Esteban et al., "Prevalence, antimicrobial resistance and serotype distribution of group b Streptococcus isolated among pregnant women and newborns in rabat, Morocco," *Journal of Medical Microbiology*, vol. 67, no. 5, pp. 652–661, 2018.
- [22] C. Li, D. Sapugahawatte, Y. Yang, K. Wong, N. Lo, and M. Ip, "Multidrug-resistant Streptococcus agalactiae strains found in human and fish with high penicillin and cefotaxime non-susceptibilities," *Microorganisms*, vol. 8, no. 7, Article ID 1055, 2020.
- [23] J. Huang, S. Li, L. Li, X. Wang, Z. Yao, and X. Ye, "Alarming regional differences in prevalence and antimicrobial susceptibility of group b streptococci in pregnant women: a systematic review and meta-analysis," *Journal of Global Antimicrobial Resistance*, vol. 7, pp. 169–177, 2016.
- [24] M. Gizachew, M. Tiruneh, F. Moges, and B. Tessema, "Streptococcus agalactiae maternal colonization, antibiotic resistance and serotype profiles in africa: a meta-analysis," *Annals of Clinical Microbiology and Antimicrobials*, vol. 18, no. 1, p. 14, 2019.
- [25] A. Elmi Farah, A. H. Abbas, and A. Tahir Ahmed, "Trends of admission and predictors of neonatal mortality: a hospital based retrospective cohort study in Somali region of Ethiopia," *PLoS One*, vol. 13, no. 9, Article ID e0203314, 2018.
- [26] R. Beigverdi, F. Jabalameli, A. Mirsalehian et al., "Virulence factors, antimicrobial susceptibility and molecular characterization of Streptococcus agalactiae isolated from pregnant women," *Acta Microbiologica et Immunologica Hungarica*, vol. 61, no. 4, pp. 425–434, 2014.
- [27] ACOG, "Prevention of group b streptococcal early-onset disease in newborns," *Journal of Clinical Microbiology*, vol. 134, no. 1, pp. 1–22, 2019.
- [28] ASM, "Guidelines for the Detection and Identification of Group B Streptococcus," 2021, <https://asm.org/Guideline/Guidelines-for-the-Detection-and-Identification-of-gbs>.
- [29] P. Wayne, "Performance standards for antimicrobial susceptibility testing. Clsi approved standard m100–s23," *Clin Lab Stand Inst*, vol. 33, pp. 118–156, 2013.
- [30] CLSI, *Performance Standards for Antimicrobial Susceptibility Testing*, Clinical and Laboratory Standards Institute, Wayne, PA, USA, 30th edition, 2020.
- [31] K. Le Doare, S. Jarju, S. Darboe et al., "Risk factors for group b Streptococcus colonisation and disease in gambian women and their infants," *Journal of Infection*, vol. 72, no. 3, pp. 283–294, 2016.
- [32] T. Dzowela, O. Komolafe, and A. Igbigbi, "Prevalence of group b Streptococcus colonization in antenatal women at the queen elizabeth central hospital, blantyre—a preliminary study," *Malawi Medical Journal*, vol. 17, no. 3, pp. 97–99, 2015.
- [33] N. M. Nkembe, H. G. Kamga, W. A. Baiye, A. B. Chafa, and P. N. Njotang, "Streptococcus agalactiae prevalence and antimicrobial susceptibility pattern in vaginal and anorectal swabs of pregnant women at a tertiary hospital in Cameroon," *BMC Research Notes*, vol. 11, no. 1, p. 480, 2018.
- [34] G. Alemseged, S. Niguse, H. Hailekiros, M. Abdulkadir, M. Saravanan, and T. Asmelash, "Isolation and anti-microbial susceptibility pattern of group b Streptococcus among pregnant women attending antenatal clinics in ayder referral hospital and mekelle health center, mekelle, northern Ethiopia," *BMC Research Notes*, vol. 8, no. 1, p. 518, 2015.
- [35] T. A. Yadeta, A. Worku, G. Egata, B. Seyoum, D. Marami, and Y. Berhane, "Maternal group b Streptococcus recto vaginal colonization increases the odds of stillbirth: evidence from eastern Ethiopia," *BMC Pregnancy and Childbirth*, vol. 18, no. 1, p. 410, 2018.
- [36] J. B. Namavar, S. Pourarian, and S. Pourbarfehei, "The prevalence and adverse effects of group b streptococcal colonization during pregnancy," *Archives of Iranian Medicine*, vol. 11, no. 6, pp. 654–657, 2008.
- [37] A. C. Seale, A. C. Koech, A. E. Sheppard et al., "Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya," *Nature Microbiology*, vol. 1, no. 7, pp. 16067–16110, 2016.
- [38] K. O. Okon, H. Usman, Z. Umar, and S. T. Balogun, "Prevalence of Group B Streptococci (GBS) colonization among pregnant women attending antenatal clinic of a tertiary hospital in northeastern Nigeria," *American Journal of Research Communication*, vol. 1, no. 6, pp. 54–66, 2013.
- [39] M. Gizachew, M. Tiruneh, F. Moges, M. Adefris, Z. Tigabu, and B. Tessema, "Proportion of Streptococcus agalactiae vertical transmission and associated risk factors among ethiopian mother-newborn dyads, northwest Ethiopia," *Scientific Reports*, vol. 10, no. 1, pp. 3477–3478, 2020.
- [40] M. M. Ali, D. Asrat, D. A. Fenta, T. E. Chaka, and Y. Woldeamanuel, "Group b Streptococcus colonization rate and serotype distribution among pregnant women and their newborns at adama hospital medical college, Ethiopia," *Scientific Reports*, vol. 10, no. 1, pp. 9301–9307, 2020.
- [41] M. A. Khan, A. Faiz, and A. M. Ashshi, "Maternal colonization of group b Streptococcus: prevalence, associated factors and antimicrobial resistance," *Annals of Saudi Medicine*, vol. 35, no. 6, pp. 423–427, 2015.
- [42] M. I. Matee, F. A. Massawe, and E. F. Lyamuya, "Maternal and neonatal colonisation of group b Streptococcus at muhimbili national hospital in dar es salaam, Tanzania: prevalence, risk factors and antimicrobial resistance," *BMC Public Health*, vol. 9, no. 1, p. 437, 2009.
- [43] M. Salat, "Prevalence of Gbs colonization in antenatal women at Kenyatta national hospital," Masters Thesis, University of Nairobi, Nairobi, Kenya, 2009.
- [44] I. M. Ezeonu and M. C. Agbo, "Incidence and anti-microbial resistance profile of group b Streptococcus (gbs) infection in pregnant women in nsukka, enugu state, Nigeria," *African Journal of Microbiology Research*, vol. 8, no. 1, pp. 91–95, 2014.
- [45] J. A. N. Banini and E. H. Frimpong, *Carriage and Antibiotic Susceptibility Profile of Group B Streptococcus during Late Pregnancy in Selected Hospitals in Greater Accra*, 2015.
- [46] M. Gizachew, M. Tiruneh, F. Moges, M. Adefris, Z. Tigabu, and B. Tessema, "Streptococcus agalactiae from ethiopian pregnant women; prevalence, associated factors and antimicrobial resistance: alarming for prophylaxis," *Annals of Clinical Microbiology and Antimicrobials*, vol. 18, no. 1, p. 3, 2019.
- [47] A. Mengist, H. Kannan, and A. Abdissa, "Prevalence and antimicrobial susceptibility pattern of anorectal and vaginal group b streptococci isolates among pregnant women in jimma, Ethiopia," *BMC Research Notes*, vol. 9, no. 1, p. 351, 2016.
- [48] T. Kahsay Gebremeskel, T. A. Zeleke, A. Mihret, and M. D. Tikue, "Prevalence and antibiotic susceptibility pattern of Streptococcus agalactiae among pregnant women at adigrat zonal hospital and adigrat health center, tigray, Ethiopia,"

- Journal of Gynecology and Obstetrics*, vol. 3, no. 2, pp. 29–35, 2015.
- [49] S. Fröhlicher, G. Reichen-Fahrni, M. Müller et al., “Serotype distribution and antimicrobial susceptibility of group b streptococci in pregnant women: results from a swiss tertiary centre,” *Swiss Medical Weekly*, vol. 144, no. w13935, 2014.
- [50] S. Mohamed Sadaka, H. Abdelsalam Aly, M. Ahmed Meheissen, Y. I. Orief, and B. Mohamed Arafa, “Group b streptococcal carriage, antimicrobial susceptibility, and virulence related genes among pregnant women in alexandria, Egypt,” *Alexandria Journal of Medicine*, vol. 54, no. 1, pp. 69–76, 2018.
- [51] S. C. Jisuvei, A. Osoti, and M. A. Njeri, “Prevalence, antimicrobial susceptibility patterns, serotypes and risk factors for group b Streptococcus rectovaginal isolates among pregnant women at kenyatta national hospital, Kenya; a cross-sectional study,” *BMC Infectious Diseases*, vol. 20, pp. 1–9, 2020.
- [52] S. Assefa, K. Desta, and T. Lema, “Group b streptococci vaginal colonization and drug susceptibility pattern among pregnant women attending in selected public antenatal care centers in addis ababa, Ethiopia,” *BMC Pregnancy and Childbirth*, vol. 18, no. 1, p. 135, 2018.
- [53] M. Gizachew, M. Tiruneh, F. Moges, M. Adefris, Z. Tigabu, and B. Tessema, “Newborn colonization and antibiotic susceptibility patterns of Streptococcus agalactiae at the university of gondar referral hospital, northwest Ethiopia,” *BMC Pediatrics*, vol. 18, no. 1, pp. 378–411, 2018.
- [54] A. C. N. Botelho, J. G. Oliveira, A. P. Damasco et al., “Streptococcus agalactiae carriage among pregnant women living in rio de janeiro, Brazil, over a period of eight years,” *PLoS One*, vol. 13, no. 5, Article ID e0196925, 2018.
- [55] W. Dai, Y. Zhang, Y. Xu, M. Zhu, X. Rong, and Q. Zhong, “The effect of group B streptococci on maternal and infants’ prognosis in Guizhou, China,” *Bioscience Reports*, vol. 39, no. 12, 2019.
- [56] T. C. Dechen, K. Sumit, and P. Ranabir, “Correlates of vaginal colonization with group b streptococci among pregnant women,” *Journal of Global Infectious Diseases*, vol. 2, no. 3, pp. 236–41, 2010.
- [57] W. Girma, N. Yimer, T. Kassa, and E. Yesuf, “Group b Streptococcus recto-vaginal colonization in near-term pregnant women, southwest Ethiopia,” *Ethiopian Journal of Health Sciences*, vol. 30, no. 5, pp. 687–696, 2020.